Exelixis Inc. (NASDAQ: EXEL) shares dipped on Monday after the company announced that it has initiated a late-stage trial in patients with radioiodine-refractory differentiated thyroid cancer (DTC).
This Phase 3 trial (COSMIC-311) of single-agent cabozantinib is specifically designed for DTC patients who have progressed after up to two prior vascular endothelial growth factor receptor (VEGFR)-targeted therapies.
So far, cabozantinib has demonstrated encouraging clinical activity in patients with radioiodine-refractory DTC in Phase 1 and 2 studies, suggesting it may be a promising treatment option for patients who have progressed after prior VEGFR-targeting therapy.
Management is looking forward to enrolling patients in this global trial to learn more about the potential of cabozantinib for this intractable form of thyroid cancer.
Marcia Brose, M.D., Ph.D., Associate Professor of Otorhinolaryngology: Head and Neck Surgery and Director of the Center for Rare Cancers and Personalized Therapy at the Abramson Cancer Center of the University of Pennsylvania, and principal investigator of the trial, commented:
With the incidence of thyroid cancer increasing more rapidly than any other type of cancer in the U.S., and limited options available to patients whose disease has progressed following anti-VEGFR therapy, there is an urgent need for new treatments. Given the positive results from earlier stage trials, we are eager to learn more from this phase 3 study about cabozantinib’s potential benefit in this patient population.
Excluding Monday’s move, Exelixis shares have underperformed the broad markets, with the stock down 31.5% in the past 52 weeks. In just 2018 alone, the stock is down 42% year to date.
Shares of Exelixis were last seen down about 1% at $17.47, with a consensus analyst price target of $29.22 and a 52-week trading range of $15.81 to $32.50.
Sponsored: Tips for Investing
A financial advisor can help you understand the advantages and disadvantages of investment properties. Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to three financial advisors who serve your area, and you can interview your advisor matches at no cost to decide which one is right for you. If you’re ready to find an advisor who can help you achieve your financial goals, get started now.
Investing in real estate can diversify your portfolio. But expanding your horizons may add additional costs. If you’re an investor looking to minimize expenses, consider checking out online brokerages. They often offer low investment fees, helping you maximize your profit.